EC Number   |
Inhibitors |
Structure |
|---|
   3.1.1.34 | 1,1'-bis(anilino)-4-,4'-bis(naphthalen)-8,8'-disulfonate |
0.01-0.015 mM, almost complete inhibition of tributyrin and tripropionin hydrolysis, competes for binding with apoprotein CII, inhibition is prevented or restored by apoprotein CII |
   |
| 3.1.1.34 | 2-mercaptoethanol |
- |
|
| 3.1.1.34 | 3-[4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)biphenyl-3-yl]propanoic acid |
- |
|
| 3.1.1.34 | 4-ethylphenylboronic acid |
- |
|
| 3.1.1.34 | 4-nonylphenylboronic acid |
- |
|
| 3.1.1.34 | 4-tert-butyl-N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)phenyl]benzamide |
- |
|
| 3.1.1.34 | 5,5'-dithiobis(2-nitrobenzoate) |
- |
|
| 3.1.1.34 | angiopoietin-like protein 3 |
mainly exhibits reversible inhibition of the catalytic activity of LPL, heparin is able to overcome the inhibitory effect of angiopoietin-like protein 3 on LPL at a concentration as low as 0.8 units/ml |
|
| 3.1.1.34 | angiopoietin-like protein 3 |
i.e. Angptl3, human, commercial preparation of recombinant enzyme, inhibits LPL activity in vitro and in vivo, structural basis for inhibition, overview. The highly conserved motif LAXGLLXLGXGL, where X represents polar amino acid residues, corresponding to amino acid residues 46-57 within the NH2-terminal coiled-coil domain, confers its inhibitory effects on lipoprotein lipase |
|
| 3.1.1.34 | angiopoietin-like protein 3 |
ANGPTL3 causes reduction of the activity of LPL via a two-step mechanism |
|
